Seaport Research Partners initiated coverage of Nebius Group N.V. with a rating of Neutral

Goldman initiated coverage of Nebius Group N.V. with a rating of Buy and set a new price target of $68.00

Arete initiated coverage of Nebius Group N.V. with a rating of Buy and set a new price target of $84.00

Northland Capital initiated coverage of Nebius Group N.V. with a rating of Outperform and set a new price target of $34.00

DA Davidson initiated coverage of Nebius Group N.V. with a rating of Buy and set a new price target of $50.00

BWS Financial reiterated coverage of Nebius Group N.V. with a rating of Buy and set a new price target of $60.00 from $51.00 previously

BWS Financial initiated coverage of Nebius Group N.V. with a rating of Buy and set a new price target of $51.00

Nebius Group N.V. (("Nebius Group" or the "Company", NASDAQ:NBIS) will release its third quarter 2025 financial results on Tuesday, November 11, 2025, before market open. Nebius Group will also hold a conference call to discuss its results at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time / 2:00 p.m. Central European Time) on the same day. The registration link to access the webcast and its replay will be available on Nebius Group's Investor Relations website at https://nebius.com/investor-hub. About Nebius Group Nebius Group (NASDAQ:NBIS) is a technology company building full-stack infrastructure for the global AI industry. Headquartered in Amsterdam and listed on Nasdaq, Nebius Grou

Enables significant and rapid scaling of Avride's business to capitalize on substantial market opportunity in autonomous driving technologies and services. Avride, a leading developer of autonomous driving technologies, has secured strategic investments and commercial commitments from Uber Technologies, Inc. and Nebius Group. The transaction totals up to $375 million from Uber and Nebius. It builds on Avride's commercial partnership with Uber, following the signing of a multi-year strategic agreement in 2024. The launch of Avride's robotaxi service on the Uber platform is planned in Dallas by the end of 2025. Avride's delivery robots are already fulfilling orders through the Uber Eats

Certifications such as SOC 2 Type II including HIPAA, and ISO 27001 enable AI deployment in highly regulated contexts including healthcare, financial services, and government Enhanced observability and Identity and Access Management (IAM) provide more granular control, while streamlined developer workflows accelerate time to production with simplified UI and app catalogue Platform resilience further strengthened with proactive system health monitoring, self-healing infrastructure, and substantial performance gains across storage systems. Nebius today announced Nebius AI Cloud 3.0 "Aether", the latest release of Nebius AI Cloud, delivering enterprise-grade features that give organi

TD SYNNEX Partners with Nebius to Bring the High-Performance AI Cloud to IT Ecosystem TD SYNNEX (NYSE:SNX) announces the launch of its AI Infrastructure-as-a-Service (AI IaaS) offering in North America, enabling TD SYNNEX partners to deliver advanced, secure, and cost-optimized AI solutions without the upfront burden of hardware investment. This is made possible through a new partnership with Nebius (NASDAQ:NBIS), an AI cloud service provider that delivers cost-efficient, full-stack AI cloud combining hyperscaler flexibility with supercomputer performance. With demand for artificial intelligence surging across industries, TD SYNNEX now equips partners with access to Nebius AI Cloud, bui

New York, Oct. 07, 2025 (GLOBE NEWSWIRE) -- GraniteShares 2x Long ISRG Daily ETF (ISUL) and GraniteShares 2x Long NBIS Daily ETF (NBIL) Launch Today. GraniteShares, a provider of exchange traded funds (ETFs), today announced the launch of two new leveraged single-stock ETFs:GraniteShares 2x Long ISRG Daily ETF (NASDAQ:ISUL), and GraniteShares 2x Long NBIS Daily ETF (NASDAQ:NBIL) An investment in these ETFs provides investors daily leveraged exposure to the two respective underlying stocks: Intuitive Surgical, Inc. (NASDAQ:ISRG) and Nebius Group NV (NASDAQ:NBIS). GraniteShares' leveraged ETFs seek daily investment results, before fees and expenses, that correspond to 2 times (200%) the

Nebius Group N.V. (("Nebius Group" or the "Company", NASDAQ:NBIS), a leading AI infrastructure company, today announced that, in connection with its previously announced underwritten public offering of Class A ordinary shares, the underwriters have exercised in full their option to purchase an additional 1,621,621 Class A shares at the offering price of $92.50, less underwriting discounts and commissions, bringing Nebius's aggregate gross proceeds from the Class A offering to approximately $1.15 billion. The initial closing of the Class A offering occurred on September 15, at which time the Company also closed its offering of convertible notes due 2030 and 2032 to qualified institutional bu

Single-stock funds seek to provide 200% long exposure on a variety of industry leaders NEW YORK, Sept. 16, 2025 /PRNewswire/ -- Tradr ETFs, a provider of ETFs designed for sophisticated investors and professional traders, today announced the launch of five new single stock leveraged ETFs. All five funds are first-to-market strategies and will be listed on Cboe. The funds aim to deliver twice (200%) the daily performance of a specific underlying stock. Tradr launches: Tradr 2X Long CLSK Daily ETF (Cboe: CLSX) – tracks CleanSpark, Inc. (NASDAQ:CLSK)Tradr 2X Long CRDO Daily ETF (Cboe: CRDU) – tracks Credo Technology (NASDAQ:CRDO)Tradr 2X Long ENPH Daily ETF (Cboe: ENPX) – tracks Enphase Energy,

Nebius Group N.V. (("Nebius Group" or the "Company", NASDAQ:NBIS), a leading AI infrastructure company, today announced the closing of its previously announced underwritten public offering of 10,810,811 Class A ordinary shares at an offering price of $92.50 per Class A share. The underwriters of such offering have a 30-day option (starting from September 10, 2025) to purchase up to an additional 1,621,621 Class A shares at the offering price, less underwriting discounts and commissions. The Company also announced the closing of its previously announced offering of convertible senior notes, in two series: 1.00% convertible notes due 2030 (the "2030 Notes") and 2.75% convertible notes due 203

MarketNewsUpdates News Commentary NEW YORK, Sept. 11, 2025 /PRNewswire/ -- The global Diagnostic Biomarker market is experiencing unprecedented growth and is projected to continue to see substantial growth in years to come. A recent report from the (NIH) National Library of Medicine discussed the AI-Assisted Biomarker, said that: "Recently, advancements in healthcare digitization and personalized treatments have led to groundbreaking developments. Utilization of AI and ML has the potential to enhance comprehension of disease onset and progression, potentially uncovering new disease subtypes, unveiling novel drug targets, advancing the field of precision medicine, propelling efforts towards d

Nebius Group N.V. (("Nebius Group" or the "Company", NASDAQ:NBIS), a leading AI infrastructure company, today announced the pricing of its offering of $2.75 billion aggregate original principal amount of convertible senior notes, in two series: $1,375,000,000 aggregate original principal amount of 1.00% convertible notes due 2030 (the "2030 Notes") and $1,375,000,000 aggregate original principal amount of 2.75% convertible notes due 2032 (the "2032 Notes", and together with the 2030 Notes, the "Notes"), in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The offering was upsized from the previousl

6-K - Nebius Group N.V. (0001513845) (Filer)

6-K - Nebius Group N.V. (0001513845) (Filer)

6-K - Nebius Group N.V. (0001513845) (Filer)

FWP - Nebius Group N.V. (0001513845) (Subject)

FWP - Nebius Group N.V. (0001513845) (Subject)

FWP - Nebius Group N.V. (0001513845) (Subject)

424B5 - Nebius Group N.V. (0001513845) (Filer)

FWP - Nebius Group N.V. (0001513845) (Subject)

FWP - Nebius Group N.V. (0001513845) (Subject)

FWP - Nebius Group N.V. (0001513845) (Subject)

Nebius (NASDAQ:NBIS), a leading AI infrastructure company, today announced the appointment of Marc Boroditsky as Chief Revenue Officer as the company continues to build out its global sales team. A seasoned senior tech executive, Marc has a strong global go-to-market track record of driving high growth – in five years at Twilio he grew paying customers six times, and revenue more than 10 times to $4 billion. Previously he founded several successful companies, and served as a senior leader at Oracle and most recently Cloudflare. Arkady Volozh, founder and CEO of Nebius, welcomed Marc to the company: "We are building a global company and planning to grow many times in the coming years.

SC 13G/A - Nebius Group N.V. (0001513845) (Subject)

Nebius Group N.V. (("Nebius Group" or the "Company", NASDAQ:NBIS) will release its third quarter 2025 financial results on Tuesday, November 11, 2025, before market open. Nebius Group will also hold a conference call to discuss its results at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time / 2:00 p.m. Central European Time) on the same day. The registration link to access the webcast and its replay will be available on Nebius Group's Investor Relations website at https://nebius.com/investor-hub. About Nebius Group Nebius Group (NASDAQ:NBIS) is a technology company building full-stack infrastructure for the global AI industry. Headquartered in Amsterdam and listed on Nasdaq, Nebius Grou

MarketNewsUpdates News Commentary NEW YORK, Sept. 11, 2025 /PRNewswire/ -- The global Diagnostic Biomarker market is experiencing unprecedented growth and is projected to continue to see substantial growth in years to come. A recent report from the (NIH) National Library of Medicine discussed the AI-Assisted Biomarker, said that: "Recently, advancements in healthcare digitization and personalized treatments have led to groundbreaking developments. Utilization of AI and ML has the potential to enhance comprehension of disease onset and progression, potentially uncovering new disease subtypes, unveiling novel drug targets, advancing the field of precision medicine, propelling efforts towards d

Annualized run-rate revenue(1) (ARR) guidance increased to $900 million to $1.1 billion for the end of 2025 Revenue for Q2 of $105.1 million, up 625% year-on-year and 106% quarter-on-quarter Core business achieves positive Adjusted EBITDA ahead of plan In the process of securing more than 1 GW of power by the end of 2026 Nebius Group N.V. (NASDAQ:NBIS), a leading AI infrastructure company, today announced its unaudited financial results for the second quarter ended June 30, 2025. "Nebius is continuing to deliver exceptional results," said founder and CEO Arkady Volozh. "In Q2 we more than doubled revenue from the previous quarter, and our core business achieved positive Adjus